Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: A plurality of PCIe switch complexes are interposed between a plurality of I/O devices and a plurality of microprocessor complexes. Each PCIe switching complex comprises a plurality of PCIe switches wherein each switch possesses at least one non-transparent port. The non-transparent port is used to cross-couple each PCIe switch creating an active matrix of paths between the HBAs associated with each I/O device and each microprocessor. The paths between each HBA (I/O device) and each microprocessor are mapped using a recursive algorithm providing each I/O device with direct memory access to each microprocessor.

Abstract: Data buffering allocation in a microprocessor complex for a request of memory allocation is supported through a remote buffer batch allocation protocol. The separation of control and data placement allows simultaneous maximization of microprocessor complex load sharing, and minimization of inter-processor signaling/metadata migration. Separating processing control from data placement allows the location of data buffering to be chosen so as to maximize bus bandwidth utilization and achieve non-blocking switch behavior. This separation reduces the need for inter-processor communication and associated interrupts thus improving computation efficiency and performance.

Abstract: Data buffering allocation in a microprocessor complex for a request of memory allocation is supported through a remote buffer batch allocation protocol. The separation of control and data placement allows simultaneous maximization of microprocessor complex load sharing, and minimization of inter-processor signaling/metadata migration. Separating processing control from data placement allows the location of data buffering to be chosen so as to maximize bus bandwidth utilization and achieve non-blocking switch behavior. This separation reduces the need for inter-processor communication and associated interrupts thus improving computation efficiency and performance.

Abstract: Dual ported Input/Output (“I/O”) routers couple I/O devices to a cross-coupled switching fabric providing multiple levels of data path redundancy. Each I/O router possesses two or more internal ports allowing each I/O router to access multiple switches in a cross-coupled switching fabric. The additional redundant paths between each I/O device and each microprocessor complex provide additional means to balance data traffic and thereby maximize bandwidth utilization. I/O routers can be interleaved with single HBAs establishing access a switching fabric that uses cross-coupled nontransparent ports thus providing each I/O device with multiple paths upon which to pass data. Data paths are identified by a recursive address scheme that uniquely identifies each data path option available to each I/O device.

Abstract: A plurality of PCIe switch complexes are interposed between a plurality of I/O devices and a plurality of microprocessor complexes. Each PCIe switching complex comprises a plurality of PCIe switches wherein each switch possesses at least one non-transparent port. The non-transparent port is used to cross-couple each PCIe switch creating an active matrix of paths between the HBAs associated with each I/O device and each microprocessor. The paths between each HBA (I/O device) and each microprocessor are mapped using a recursive algorithm providing each I/O device with direct memory access to each microprocessor.

Abstract: Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Abstract: An algorithm for detecting a fault in an ECM output signal by determining a status of the output signal, incrementing an error timer and a retry timer when the status is abnormal, incrementing a retry counter when the retry timer reaches a maximum retry time, and reporting an intermittent fault if the retry counter reaches a retry limit before the error timer reaches an error timer maximum.

Abstract: A non-volatile data cache having a cache memory coupled to an external power source and operable to cache data of an external data device such that access requests for the data can be serviced by the cache rather than the external device. A non-volatile data storage device is coupled to the cache memory. An uninterruptible power supply (UPS) is coupled to the cache memory and the non-volatile data storage device so as to maintain the cache memory and the non-volatile storage device in an operational state for a period of time in the event of an interruption in the external power source.

Abstract: Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.